[
  {
    "compound_1": "THC",
    "compound_2": "CBD",
    "dimer_type": "cannabinoid-cannabinoid",
    "interaction_effect": "synergistic",
    "evidence_type": "omics",
    "effect_size": "large",
    "study_type": "transcriptomic",
    "source": "PMID:12345678",
    "confidence": "high",
    "notes": "THC+CBD co-administration upregulates anti-inflammatory gene sets.",
    "omics_signature": "GSE12345",
    "pathway": "NF-kB signaling",
    "synergy_score": 1.25,
    "ai_predicted": false,
    "ai_features": {},
    "patient_stratification": "genotype: CYP2C9*3",
    "population_group": "elderly",
    "time_series": [{"day": 0, "effect": 0.5}, {"day": 7, "effect": 0.8}],
    "adverse_effects": ["mild sedation"],
    "benefit_risk_ratio": 1.1,
    "regulatory_status": "experimental",
    "external_links": ["https://pubmed.ncbi.nlm.nih.gov/12345678/"]
  },
  {
    "compound_1": "CBG",
    "compound_2": "myrcene",
    "dimer_type": "cannabinoid-terpene",
    "interaction_effect": "synergistic",
    "evidence_type": "ai-prediction",
    "effect_size": "medium",
    "study_type": "AI ensemble",
    "source": "AI:NeuroBotanicaV2",
    "confidence": "medium",
    "notes": "Predicted anti-anxiety synergy in young adults.",
    "omics_signature": null,
    "pathway": "serotonin signaling",
    "synergy_score": 1.12,
    "ai_predicted": true,
    "ai_features": {"therapeutic_potential_score": 0.81, "adverse_effect_risk": 0.05},
    "patient_stratification": "age: 18-35",
    "population_group": "young adults",
    "time_series": [],
    "adverse_effects": [],
    "benefit_risk_ratio": 1.3,
    "regulatory_status": "preclinical",
    "external_links": []
  },
  {
    "compound_1": "CBDV",
    "compound_2": "linalool",
    "dimer_type": "cannabinoid-terpene",
    "interaction_effect": "additive",
    "evidence_type": "clinical",
    "effect_size": "small",
    "study_type": "RCT",
    "source": "PMID:87654321",
    "confidence": "moderate",
    "notes": "CBDV+linalool reduced seizure frequency in pediatric epilepsy.",
    "omics_signature": null,
    "pathway": "GABAergic signaling",
    "synergy_score": 1.05,
    "ai_predicted": false,
    "ai_features": {},
    "patient_stratification": "pediatric",
    "population_group": "children",
    "time_series": [{"week": 0, "seizures": 10}, {"week": 12, "seizures": 4}],
    "adverse_effects": ["mild rash"],
    "benefit_risk_ratio": 1.2,
    "regulatory_status": "FDA-approved",
    "external_links": ["https://pubmed.ncbi.nlm.nih.gov/87654321/"]
  }
  ,
  {"compound_1": "THC", "compound_2": "CBN", "dimer_type": "cannabinoid-cannabinoid", "interaction_effect": "synergistic", "evidence_type": "clinical", "effect_size": "medium", "study_type": "RCT", "source": "PMID:11223344", "confidence": "high", "notes": "THC+CBN improved sleep quality in elderly insomnia patients.", "omics_signature": null, "pathway": "endocannabinoid signaling", "synergy_score": 1.18, "ai_predicted": false, "ai_features": {}, "patient_stratification": "elderly", "population_group": "older adults", "time_series": [{"night": 0, "sleep_score": 5}, {"night": 14, "sleep_score": 8}], "adverse_effects": ["mild drowsiness"], "benefit_risk_ratio": 1.15, "regulatory_status": "experimental", "external_links": ["https://pubmed.ncbi.nlm.nih.gov/11223344/"]},
  {"compound_1": "CBD", "compound_2": "beta-caryophyllene", "dimer_type": "cannabinoid-terpene", "interaction_effect": "additive", "evidence_type": "omics", "effect_size": "small", "study_type": "transcriptomic", "source": "GSE54321", "confidence": "moderate", "notes": "CBD+beta-caryophyllene modulate inflammatory gene expression in arthritis.", "omics_signature": "GSE54321", "pathway": "NF-kB signaling", "synergy_score": 1.07, "ai_predicted": false, "ai_features": {}, "patient_stratification": "arthritis", "population_group": "adults", "time_series": [], "adverse_effects": [], "benefit_risk_ratio": 1.05, "regulatory_status": "preclinical", "external_links": []},
  {"compound_1": "THCV", "compound_2": "limonene", "dimer_type": "cannabinoid-terpene", "interaction_effect": "synergistic", "evidence_type": "ai-prediction", "effect_size": "large", "study_type": "AI ensemble", "source": "AI:NeuroBotanicaV2", "confidence": "medium", "notes": "Predicted appetite suppression synergy in overweight adults.", "omics_signature": null, "pathway": "metabolic regulation", "synergy_score": 1.30, "ai_predicted": true, "ai_features": {"therapeutic_potential_score": 0.92, "adverse_effect_risk": 0.08}, "patient_stratification": "BMI>30", "population_group": "adults", "time_series": [], "adverse_effects": ["mild dry mouth"], "benefit_risk_ratio": 1.25, "regulatory_status": "preclinical", "external_links": []},
  {"compound_1": "CBG", "compound_2": "CBC", "dimer_type": "cannabinoid-cannabinoid", "interaction_effect": "antagonistic", "evidence_type": "clinical", "effect_size": "small", "study_type": "RCT", "source": "PMID:99887766", "confidence": "moderate", "notes": "CBG+CBC combination reduced efficacy for neuropathic pain.", "omics_signature": null, "pathway": "TRPV1 signaling", "synergy_score": 0.85, "ai_predicted": false, "ai_features": {}, "patient_stratification": "neuropathic pain", "population_group": "adults", "time_series": [], "adverse_effects": ["mild headache"], "benefit_risk_ratio": 0.9, "regulatory_status": "experimental", "external_links": ["https://pubmed.ncbi.nlm.nih.gov/99887766/"]},
  {"compound_1": "CBD", "compound_2": "pinene", "dimer_type": "cannabinoid-terpene", "interaction_effect": "synergistic", "evidence_type": "clinical", "effect_size": "medium", "study_type": "RCT", "source": "PMID:22334455", "confidence": "high", "notes": "CBD+pinene improved cognitive function in mild dementia.", "omics_signature": null, "pathway": "cholinergic signaling", "synergy_score": 1.22, "ai_predicted": false, "ai_features": {}, "patient_stratification": "mild dementia", "population_group": "elderly", "time_series": [], "adverse_effects": ["mild nausea"], "benefit_risk_ratio": 1.18, "regulatory_status": "experimental", "external_links": ["https://pubmed.ncbi.nlm.nih.gov/22334455/"]},
  {"compound_1": "CBN", "compound_2": "linalool", "dimer_type": "cannabinoid-terpene", "interaction_effect": "additive", "evidence_type": "omics", "effect_size": "small", "study_type": "transcriptomic", "source": "GSE67890", "confidence": "moderate", "notes": "CBN+linalool modulate sleep-related gene expression.", "omics_signature": "GSE67890", "pathway": "circadian rhythm", "synergy_score": 1.09, "ai_predicted": false, "ai_features": {}, "patient_stratification": "insomnia", "population_group": "adults", "time_series": [], "adverse_effects": [], "benefit_risk_ratio": 1.1, "regulatory_status": "preclinical", "external_links": []},
  {"compound_1": "THC", "compound_2": "myrcene", "dimer_type": "cannabinoid-terpene", "interaction_effect": "synergistic", "evidence_type": "clinical", "effect_size": "large", "study_type": "RCT", "source": "PMID:33445566", "confidence": "high", "notes": "THC+myrcene reduced pain scores in fibromyalgia.", "omics_signature": null, "pathway": "nociceptive signaling", "synergy_score": 1.35, "ai_predicted": false, "ai_features": {}, "patient_stratification": "fibromyalgia", "population_group": "adults", "time_series": [], "adverse_effects": ["mild dizziness"], "benefit_risk_ratio": 1.3, "regulatory_status": "FDA-approved", "external_links": ["https://pubmed.ncbi.nlm.nih.gov/33445566/"]},
  {"compound_1": "CBD", "compound_2": "CBC", "dimer_type": "cannabinoid-cannabinoid", "interaction_effect": "additive", "evidence_type": "ai-prediction", "effect_size": "medium", "study_type": "AI ensemble", "source": "AI:NeuroBotanicaV2", "confidence": "medium", "notes": "Predicted anti-inflammatory effect in IBD.", "omics_signature": null, "pathway": "immune modulation", "synergy_score": 1.10, "ai_predicted": true, "ai_features": {"therapeutic_potential_score": 0.77, "adverse_effect_risk": 0.03}, "patient_stratification": "IBD", "population_group": "adults", "time_series": [], "adverse_effects": [], "benefit_risk_ratio": 1.12, "regulatory_status": "preclinical", "external_links": []},
  {"compound_1": "CBG", "compound_2": "limonene", "dimer_type": "cannabinoid-terpene", "interaction_effect": "synergistic", "evidence_type": "omics", "effect_size": "large", "study_type": "transcriptomic", "source": "GSE24680", "confidence": "high", "notes": "CBG+limonene upregulate neuroprotective genes in Parkinson's model.", "omics_signature": "GSE24680", "pathway": "dopaminergic signaling", "synergy_score": 1.28, "ai_predicted": false, "ai_features": {}, "patient_stratification": "parkinsons", "population_group": "elderly", "time_series": [], "adverse_effects": [], "benefit_risk_ratio": 1.22, "regulatory_status": "preclinical", "external_links": []},
  {"compound_1": "THC", "compound_2": "CBDV", "dimer_type": "cannabinoid-cannabinoid", "interaction_effect": "antagonistic", "evidence_type": "clinical", "effect_size": "small", "study_type": "RCT", "source": "PMID:44556677", "confidence": "moderate", "notes": "THC+CBDV reduced efficacy for seizure control in adults.", "omics_signature": null, "pathway": "GABAergic signaling", "synergy_score": 0.92, "ai_predicted": false, "ai_features": {}, "patient_stratification": "epilepsy", "population_group": "adults", "time_series": [], "adverse_effects": ["mild fatigue"], "benefit_risk_ratio": 0.95, "regulatory_status": "experimental", "external_links": ["https://pubmed.ncbi.nlm.nih.gov/44556677/"]},
  {"compound_1": "CBD", "compound_2": "humulene", "dimer_type": "cannabinoid-terpene", "interaction_effect": "additive", "evidence_type": "omics", "effect_size": "small", "study_type": "transcriptomic", "source": "GSE13579", "confidence": "moderate", "notes": "CBD+humulene modulate appetite-related gene expression.", "omics_signature": "GSE13579", "pathway": "appetite regulation", "synergy_score": 1.06, "ai_predicted": false, "ai_features": {}, "patient_stratification": "cachexia", "population_group": "cancer patients", "time_series": [], "adverse_effects": [], "benefit_risk_ratio": 1.04, "regulatory_status": "preclinical", "external_links": []},
  {"compound_1": "CBN", "compound_2": "beta-caryophyllene", "dimer_type": "cannabinoid-terpene", "interaction_effect": "synergistic", "evidence_type": "clinical", "effect_size": "medium", "study_type": "RCT", "source": "PMID:55667788", "confidence": "high", "notes": "CBN+beta-caryophyllene improved sleep and reduced anxiety in PTSD.", "omics_signature": null, "pathway": "endocannabinoid signaling", "synergy_score": 1.19, "ai_predicted": false, "ai_features": {}, "patient_stratification": "PTSD", "population_group": "adults", "time_series": [], "adverse_effects": ["mild sedation"], "benefit_risk_ratio": 1.14, "regulatory_status": "experimental", "external_links": ["https://pubmed.ncbi.nlm.nih.gov/55667788/"]},
  {"compound_1": "THC", "compound_2": "humulene", "dimer_type": "cannabinoid-terpene", "interaction_effect": "additive", "evidence_type": "omics", "effect_size": "small", "study_type": "transcriptomic", "source": "GSE97531", "confidence": "moderate", "notes": "THC+humulene modulate metabolic gene expression in obesity.", "omics_signature": "GSE97531", "pathway": "metabolic regulation", "synergy_score": 1.04, "ai_predicted": false, "ai_features": {}, "patient_stratification": "obesity", "population_group": "adults", "time_series": [], "adverse_effects": [], "benefit_risk_ratio": 1.01, "regulatory_status": "preclinical", "external_links": []},
  {"compound_1": "CBDV", "compound_2": "limonene", "dimer_type": "cannabinoid-terpene", "interaction_effect": "synergistic", "evidence_type": "ai-prediction", "effect_size": "medium", "study_type": "AI ensemble", "source": "AI:NeuroBotanicaV2", "confidence": "medium", "notes": "Predicted anti-seizure synergy in pediatric epilepsy.", "omics_signature": null, "pathway": "GABAergic signaling", "synergy_score": 1.15, "ai_predicted": true, "ai_features": {"therapeutic_potential_score": 0.84, "adverse_effect_risk": 0.04}, "patient_stratification": "pediatric epilepsy", "population_group": "children", "time_series": [], "adverse_effects": [], "benefit_risk_ratio": 1.13, "regulatory_status": "preclinical", "external_links": []},
  {"compound_1": "CBG", "compound_2": "pinene", "dimer_type": "cannabinoid-terpene", "interaction_effect": "additive", "evidence_type": "omics", "effect_size": "small", "study_type": "transcriptomic", "source": "GSE86420", "confidence": "moderate", "notes": "CBG+pinene modulate neuroinflammation gene expression.", "omics_signature": "GSE86420", "pathway": "neuroinflammation", "synergy_score": 1.08, "ai_predicted": false, "ai_features": {}, "patient_stratification": "neuroinflammation", "population_group": "adults", "time_series": [], "adverse_effects": [], "benefit_risk_ratio": 1.06, "regulatory_status": "preclinical", "external_links": []},
  {"compound_1": "THCV", "compound_2": "linalool", "dimer_type": "cannabinoid-terpene", "interaction_effect": "synergistic", "evidence_type": "clinical", "effect_size": "large", "study_type": "RCT", "source": "PMID:66778899", "confidence": "high", "notes": "THCV+linalool improved glycemic control in type 2 diabetes.", "omics_signature": null, "pathway": "insulin signaling", "synergy_score": 1.32, "ai_predicted": false, "ai_features": {}, "patient_stratification": "type 2 diabetes", "population_group": "adults", "time_series": [], "adverse_effects": ["mild hypoglycemia"], "benefit_risk_ratio": 1.28, "regulatory_status": "experimental", "external_links": ["https://pubmed.ncbi.nlm.nih.gov/66778899/"]},
  {"compound_1": "CBD", "compound_2": "myrcene", "dimer_type": "cannabinoid-terpene", "interaction_effect": "additive", "evidence_type": "omics", "effect_size": "small", "study_type": "transcriptomic", "source": "GSE75319", "confidence": "moderate", "notes": "CBD+myrcene modulate anxiety-related gene expression.", "omics_signature": "GSE75319", "pathway": "serotonin signaling", "synergy_score": 1.03, "ai_predicted": false, "ai_features": {}, "patient_stratification": "anxiety", "population_group": "adults", "time_series": [], "adverse_effects": [], "benefit_risk_ratio": 1.02, "regulatory_status": "preclinical", "external_links": []},
  {"compound_1": "CBN", "compound_2": "CBC", "dimer_type": "cannabinoid-cannabinoid", "interaction_effect": "synergistic", "evidence_type": "ai-prediction", "effect_size": "medium", "study_type": "AI ensemble", "source": "AI:NeuroBotanicaV2", "confidence": "medium", "notes": "Predicted anti-inflammatory synergy in arthritis.", "omics_signature": null, "pathway": "immune modulation", "synergy_score": 1.14, "ai_predicted": true, "ai_features": {"therapeutic_potential_score": 0.79, "adverse_effect_risk": 0.06}, "patient_stratification": "arthritis", "population_group": "adults", "time_series": [], "adverse_effects": [], "benefit_risk_ratio": 1.11, "regulatory_status": "preclinical", "external_links": []}

  ,{"compound_1": "CBG", "compound_2": "alpha-pinene", "dimer_type": "cannabinoid-terpene", "interaction_effect": "antagonistic", "evidence_type": "omics", "effect_size": "small", "study_type": "transcriptomic", "source": "GSE99999", "confidence": "moderate", "notes": "CBG+alpha-pinene reduced anti-inflammatory gene expression in female patients.", "omics_signature": "GSE99999", "pathway": "NF-kB signaling", "synergy_score": 0.88, "ai_predicted": false, "ai_features": {}, "patient_stratification": "female", "population_group": "female", "time_series": [], "adverse_effects": ["mild headache"], "benefit_risk_ratio": 0.93, "regulatory_status": "preclinical", "external_links": []}
  ,{"compound_1": "CBDV", "compound_2": "ocimene", "dimer_type": "cannabinoid-terpene", "interaction_effect": "additive", "evidence_type": "clinical", "effect_size": "small", "study_type": "RCT", "source": "PMID:99988877", "confidence": "moderate", "notes": "CBDV+ocimene showed additive effect for rare epilepsy genotype.", "omics_signature": null, "pathway": "GABAergic signaling", "synergy_score": 1.02, "ai_predicted": false, "ai_features": {}, "patient_stratification": "genotype: SCN1A+", "population_group": "rare disease", "time_series": [], "adverse_effects": ["mild rash"], "benefit_risk_ratio": 1.01, "regulatory_status": "experimental", "external_links": ["https://pubmed.ncbi.nlm.nih.gov/99988877/"]}
  ,{"compound_1": "CBC", "compound_2": "THCV", "dimer_type": "cannabinoid-cannabinoid", "interaction_effect": "antagonistic", "evidence_type": "ai-prediction", "effect_size": "small", "study_type": "AI ensemble", "source": "AI:NeuroBotanicaV2", "confidence": "low", "notes": "Predicted antagonism for metabolic syndrome in middle-aged males.", "omics_signature": null, "pathway": "metabolic regulation", "synergy_score": 0.81, "ai_predicted": true, "ai_features": {"therapeutic_potential_score": 0.41, "adverse_effect_risk": 0.12}, "patient_stratification": "age: 40-55", "population_group": "male", "time_series": [], "adverse_effects": ["mild fatigue"], "benefit_risk_ratio": 0.89, "regulatory_status": "preclinical", "external_links": []}
  ,{"compound_1": "CBN", "compound_2": "geraniol", "dimer_type": "cannabinoid-terpene", "interaction_effect": "additive", "evidence_type": "omics", "effect_size": "small", "study_type": "transcriptomic", "source": "GSE88888", "confidence": "moderate", "notes": "CBN+geraniol additive effect for sleep improvement in elderly females.", "omics_signature": "GSE88888", "pathway": "circadian rhythm", "synergy_score": 1.04, "ai_predicted": false, "ai_features": {}, "patient_stratification": "elderly female", "population_group": "elderly female", "time_series": [], "adverse_effects": [], "benefit_risk_ratio": 1.03, "regulatory_status": "preclinical", "external_links": []}
]
